Jeffrey Bennett, MD
Neurology · Aurora, CONPI 1245349620
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by AstraZeneca at 45.9% of the total. Reporting peaked in 2023 at $144,339 and has fallen 50.6% since, to $71,288 in 2025. Among neurology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 537 payments — averaging $1126.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$278K
- F. Hoffmann-la Roche AG$95K
- Amgen$72K
- Tanabe Pharma Corporation$54K
- Chugai Pharmaceutical Co., Ltd.$24K
- Genentech, Inc.$23K
- plus $59K from 16 others
Across 88 payments — averaging $14,603 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$988K
- Genentech, Inc.$154K
- UCB SA$120K
- F. Hoffmann-la Roche AG$18K
- Hoffmann-la Roche Limited$3K
- Amgen$2K
What the payments were for
- Consulting fees$239,22840%
- Speaking & faculty fees$219,10336%
- Travel & lodging$108,85818%
- Food & beverage$14,7782%
- Education$23,0044%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 317 | $277,914 |
| F. Hoffmann-la Roche AG | 43 | $95,250 |
| Amgen(2 entities) | 80 | $71,519 |
| Tanabe Pharma Corporation | 24 | $54,014 |
| Chugai Pharmaceutical Co., Ltd. | 9 | $24,328 |
| Genentech, Inc. | 17 | $23,320 |
| Roche Products Limited | 9 | $20,788 |
| Genentech USA, Inc. | 12 | $10,894 |
| AbbVie | 1 | $6,600 |
| Beigene USA, Inc. | 1 | $4,805 |
| EMD Serono, Inc. | 5 | $4,289 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 1 | $3,665 |
| Merck Kgaa | 1 | $2,650 |
| UCB SA | 1 | $2,240 |
| TG Therapeutics, Inc. | 2 | $1,979 |
| UCB Biosciences Inc. | 1 | $168 |
| UCB, Inc. | 3 | $149 |
| Bristol Myers Squibb | 5 | $116 |
| Teva Pharmaceuticals USA, Inc. | 1 | $113 |
| Argenx US, Inc. | 1 | $75 |
| Sanofi | 1 | $62 |
| Novartis | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$604,970 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnspryngSatralizumab-Mwge | 12 | $379,775 |
| Mycophenolate Mofetil | 30 | $8,595 |
| Gabapentin | 15 | $442 |
| Prednisone | 37 | $266 |
| Topiramate | 17 | $214 |
| Clonazepam | 11 | $109 |
| Diazepam | 16 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Enspryng | $10,894 | $379,77512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 neurology providers in Colorado.
Other neurology in Aurora
- Enrique AlvarezAurora$407K
- Anna ShahAurora$157K
- Timothy VollmerAurora$136K
- Simon OhAurora$112K
- Amanda PiquetAurora$106K
- Brent MorelAurora$79K
- Drew KernAurora$68K
- Ondrea TimmermannAurora$33K
- Thomas RagoleAurora$31K
- Maria NagelAurora$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.